Back

Clinical and Molecular Effects of TYK2/JAK1 Inhibition in Dermatomyositis

Mangold, A.; Vleugels, R. A.; Paik, J. J.; Shahriari, N.; Castillo, R. L.; Gehlhausen, J.; Jiang, R.; Sluzevich, J. C.; Haemel, A. K.; Fox, J. C.; Bogle, R.; Roberts, B. T.; Penner, S.; Li, X.; Ramirez, Z.; Tsoi, A.; Shaw, K.; Cascino, M.; Johnson, B. M.; Kahlenberg, J. M.; Christopher-Stine, L.; Fernandez, A. P.; Fiorentino, D. F.; Werth, V. P.; Gudjonsson, J. E.

2026-06-26 dermatology
10.64898/2026.06.15.26354270 medRxiv
Show abstract

Dermatomyositis is driven by overactivation of type I and II interferons and other proinflammatory cytokines that signal via the JAK-STAT pathway. We conducted a 12-week, open-label study of brepocitinib, an oral TYK2/JAK1 inhibitor, in five adults with severe cutaneous dermatomyositis. Treatment was associated with rapid, clinically meaningful improvement in cutaneous disease activity. Single-cell and spatial transcriptomic profiling of lesional skin showed marked suppression of interferon-responsive pathways and inflammatory cell states by week 4. Together with findings from a Phase 3 randomized trial in DM patients with skin and muscle involvement (VALOR, NCT05437263), these data support TYK2/JAK1 inhibition as a promising therapeutic strategy for DM.

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.